These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11526386)

  • 1. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiple sclerosis--recent advances in pathogenesis and treatment].
    Itoyama Y; Fujihara K; Nakashima I; Misu T; Fujimori T; Sato S
    No To Shinkei; 2002 Jan; 54(1):5-21. PubMed ID: 11868352
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple sclerosis].
    Tanosaki M; Matsunaga M
    Nihon Rinsho; 2004 May; 62 Suppl 5():586-9. PubMed ID: 15197989
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5631-5. PubMed ID: 9863301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple sclerosis].
    Ochi H; Kira J
    Ryoikibetsu Shokogun Shirizu; 2000; (31):47-51. PubMed ID: 11269138
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
    Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
    J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells and microglia as drivers of multiple sclerosis pathology.
    Friese MA; Fugger L
    Brain; 2007 Nov; 130(Pt 11):2755-7. PubMed ID: 17956912
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor necrosis factor: immunogenetics and disease.
    Hauser SL
    Ann Neurol; 1995 Nov; 38(5):702-4. PubMed ID: 7486860
    [No Abstract]   [Full Text] [Related]  

  • 11. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
    Kohm AP; Turley DM; Miller SD
    Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: human model for EAE?
    Hohlfeld R
    Eur J Immunol; 2009 Aug; 39(8):2036-9. PubMed ID: 19672899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic aspects of multiple sclerosis.
    Taylor RS
    Phys Med Rehabil Clin N Am; 1998 Aug; 9(3):525-36, v. PubMed ID: 9894106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical immunological and immunogenetical aspects of neurological diseases.
    Péterfalvi A
    Ideggyogy Sz; 2010 Jan; 63(1-2):52-60. PubMed ID: 20420125
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.
    Mirandola SR; Hallal DE; Farias AS; Oliveira EC; Brandão CO; Ruocco HH; Damasceno BP; Santos LM
    Int Immunopharmacol; 2009 Jul; 9(7-8):824-30. PubMed ID: 19289181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical consultations: multiple sclerosis.
    Wingerchuk DM; Carter JL
    Semin Neurol; 2003 Sep; 23(3):253-64. PubMed ID: 14722821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of arthritis: recent research progress.
    Feldmann M
    Nat Immunol; 2001 Sep; 2(9):771-3. PubMed ID: 11526382
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple sclerosis: where will we be in 2020?
    Miller AE
    Mt Sinai J Med; 2011; 78(2):268-79. PubMed ID: 21425270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytokines slow down the progression of MS. Successful animal experiments with a vaccine].
    Orn P
    Lakartidningen; 1996 Feb; 93(7):573-5. PubMed ID: 8642918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.